Charnwood Molecular is delighted to have recently expanded its commercial team, with two senior appointments in business development roles, to strengthen the company’s global operations.
Melody McDonough joins the team as Business Development Director. Melody is based in the North Carolina area and covers the US territory for Charnwood Molecular.
Melody has extensive experience in business development, with previous roles working in end-to-end discovery, development and manufacturing CROs with a focus in the small molecule space. She is also a co-Founder of a not-for-profit corporation, organised and operated specifically to allow children and young adults to build self-esteem and confidence.
She is joined by another recruit to our business development team in Linos Lazarides.
Linos joins Charnwood Molecular as Senior Business Development Executive, with responsibilities in Europe.
He has previous business development experience in providing medicinal and synthetic chemistry and preclinical integrated drug discovery projects. Prior to that, Linos worked at GSK and then Selcia Ltd as a medicinal chemist.
These two new appointments will enable Charnwood Molecular to deliver its ambitious growth plan, promoting the company as a trusted partner in innovative chemistry, working alongside expert CRO providers in other drug discovery disciplines, to deliver drug candidates to clinical stages in accelerated timelines.
“We are delighted that Melody and Linos have joined us at such an exciting time for the company,” said Dr Robin Wilkes, Director of Business Development. “Both bring exceptional experience and relationships in our sector and their involvement will enable better coverage of our key client territories in both the USA and Europe for Charnwood Molecular”, he added.
Charnwood Molecular has seen significant expansion of its global client base in recent years and the expansion of the business development team will further support continued growth in our wide range of contract research services, from medicinal chemistry, chemical development and early process research to providing other bespoke synthetic chemistry support for our international clients.